Form 4: Iteos Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Aaron I. Davis acquired stock options in Iteos Therapeutics, Inc. on June 11, 2024.
Summary
- On June 11, 2024, Aaron I. Davis, a director of Iteos Therapeutics, Inc., acquired 24,200 stock options.
- The exercise price of these options is $16.32.
- The options become exercisable on June 11, 2025, and expire on June 11, 2034.
- Following the transaction, Davis directly owns 24,200 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating a director's acquisition of stock options, which can be seen as a moderately positive sign of confidence, but it's not a major event.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in the biopharmaceutical industry. Monitoring such transactions can provide insights into management's perspective on the company's prospects.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of transaction: Aaron I. Davis acquired stock options. |
| 06/11/2025 | Date the stock options become exercisable. |
| 06/11/2034 | Expiration date of the stock options. |
| 06/13/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.